DIN 02533448 — ULTOMIRIS 300 MG
ULTOMIRIS is a solution of Ravulizumab marketed by ALEXION PHARMA GMBH. The full Ravulizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02533448
- Brand name
- ULTOMIRIS
- Active ingredient
- Ravulizumab
- Strength
- 300 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- ALEXION PHARMA GMBH
- Health Canada status
- MARKETED
- Drug class
- Terminal complement inhibitor (anti-C5 monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Ravulizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02533456 | ULTOMIRIS | 1100 MG | SOLUTION | ALEXION PHARMA GMBH | MARKETED |